---
layout: default
title: Buprenorphine Hydrochloride
parent: 僅模型預測 (L5)
nav_order: 37
evidence_level: L5
indication_count: 0
---

# Buprenorphine Hydrochloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Buprenorphine Hydrochloride: Drug Repurposing Evaluation — Insufficient Data for Full Assessment

---

## One-Sentence Summary

Buprenorphine Hydrochloride is a well-known partial opioid agonist used clinically for opioid use disorder and pain management.
However, the current Evidence Pack contains **no TxGNN predicted indications**, and critical drug-level data — including original approved indications and mechanism of action — are absent from the structured data fields.
A complete repurposing evaluation **cannot be conducted** at this stage; this report summarises what is available and outlines what is needed to proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not populated in current Evidence Pack |
| Predicted New Indication | Not available — TxGNN predictions absent |
| TxGNN Prediction Score | Not available |
| Evidence Level | Not evaluable |
| Taiwan Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why the Data Gap Matters

Without a predicted indication from TxGNN, this report cannot fulfil its core purpose: explaining why a drug's mechanism might extend to a new disease area.

The query log does show that both a DrugBank lookup and a TFDA package insert query returned **1 result each**, meaning raw data likely exists upstream. However, neither the mechanism of action nor the approved indication text was propagated into the Evidence Pack fields. Until those fields are populated, mechanistic reasoning is not possible.

> Currently, detailed mechanism of action data is not available in the structured Evidence Pack.
> Based on general pharmaceutical knowledge, Buprenorphine Hydrochloride is a **partial agonist at μ-opioid receptors** and an **antagonist at κ-opioid receptors**, approved in many jurisdictions for opioid use disorder (OUD) and chronic pain.
> Its repurposing potential — for example in treatment-resistant depression or neonatal abstinence syndrome management — is an active area of clinical research, but **no formal TxGNN prediction is recorded here** to anchor this evaluation.

---

## Taiwan Market Information

No authorizations were found in the Taiwan TFDA database. Buprenorphine Hydrochloride is **not currently marketed in Taiwan** under any registered product.

---

## Safety Considerations

Please refer to the package insert for safety information.

> Note: The TFDA package insert query returned 1 result, but the warnings and contraindications fields were not populated in this Evidence Pack. This is a pipeline data extraction issue rather than a genuine absence of safety information for this drug class.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack is critically incomplete on all evaluable dimensions — no TxGNN predictions, no original indication, no MOA, and no safety data. Issuing a Go or Proceed-with-Guardrails recommendation without these inputs would not be clinically responsible.

**To proceed, the following is needed:**

- **TxGNN predictions**: Re-run the model for Buprenorphine Hydrochloride and confirm at least one predicted indication with score and evidence links
- **Original indication**: Extract from the TFDA package insert result already retrieved (query ID 4, status: success) — the text needs to be parsed into `drug.original_indications`
- **Mechanism of action**: Extract from the DrugBank result already retrieved (query ID 3, status: success) — populate `drug.original_moa`
- **Safety data**: Parse key warnings and contraindications from the same package insert source — populate `safety.key_warnings` and `safety.contraindications`
- **DDI data**: The DDI query returned not_found; consider querying a secondary source (e.g. DrugBank interaction API or FDA label) given that buprenorphine has clinically significant interactions with CNS depressants and CYP3A4 inhibitors
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

